Pancreatic Cancer Research

ResearcherKorea Advanced Institute of Science and TechnologyActive in the last 2 years

Jeong Youp Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0110-8606; OpenAlex author ID A5089138431. Sources: OpenAlex.

Their work

Papers
59 (first author 2, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
105
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 5 papers · 2014: 7 papers · 2015: 1 paper · 2016: 6 papers · 2017: 5 papers · 2018: 2 papers · 2019: 3 papers · 2020: 7 papers · 2021: 5 papers · 2022: 5 papers · 2023: 3 papers · 2024: 4 papers · 2025: 2 papers · 2026: 1 paper

Papers 50 of 59

  1. FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study. Co-author DOI 10.1016/j.tranon.2026.103085↗
  2. Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine learning model. Co-author DOI 10.1186/s12885-025-15285-4↗
  3. Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer. Co-author DOI 10.1186/s12943-025-02374-y↗
  4. Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70363↗
  5. Uncovering the clinicopathological features of early recurrence after surgical resection of pancreatic cancer. Co-author DOI 10.1038/s41598-024-52909-4↗
  6. Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study. Co-author DOI 10.1177/17588359241279688↗
  7. Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with … Co-author DOI 10.1186/s13073-024-01287-7↗
  8. Difference of Risk of Pancreatic Cancer in New-Onset Diabetes and Long-standing Diabetes: A Population-based Cohort Study. Co-author DOI 10.1210/clinem/dgac728↗
  9. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  10. Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective stud… Co-author DOI 10.3389/fonc.2023.1206565↗
  11. A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.34144↗
  12. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. Co-author DOI 10.3390/cancers14010236↗
  13. Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Co-author DOI 10.3390/cancers14051244↗
  14. Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer. Co-author DOI 10.3390/cancers14194672↗
  15. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. Co-author DOI 10.5009/gnl20301↗
  16. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103218↗
  17. Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jgh.15265↗
  18. Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population. Co-author DOI 10.1177/0284185120917118↗
  19. Complete response of locally advanced left-sided pancreatic cancer after modified FOLFIRINOX chemotherapy followed by conversion surgery: A case report. First author DOI 10.14701/ahbps.2021.25.3.390↗
  20. Usefulness of Smartphone Apps for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial. Co-author DOI 10.2196/21088↗
  21. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer. Co-author DOI 10.1007/s00280-020-04051-x↗
  22. Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing bloc… Co-author DOI 10.1016/j.pan.2020.05.017↗
  23. Lewis Antigen Phenotype and Survival of Patients With Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001687↗
  24. Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.1111/jgh.14837↗
  25. Neoadjuvant chemotherapy followed by total pancreatectomy with splenectomy and combined vascular resections after preoperative percutaneous transhepatic portal… Co-author DOI 10.14701/ahbps.2020.24.4.551↗
  26. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. Co-author DOI 10.4251/wjgo.v12.i2.182↗
  27. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer. Co-author DOI 10.5009/gnl18419↗
  28. Establishment of pancreatic cancer cell lines with endoscopic ultrasound-guided biopsy via conditionally reprogrammed cell culture. Co-author DOI 10.1002/cam4.2210↗
  29. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy. Co-author DOI 10.1080/01635581.2019.1597906↗
  30. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001319↗
  31. Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Co-author DOI 10.1038/s41598-018-21823-x↗
  32. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. Last author DOI 10.4251/wjgo.v10.i11.421↗
  33. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A sing… Co-author DOI 10.1053/j.seminoncol.2018.01.001↗
  34. The Significance of the Prognostic Nutritional Index for All Stages of Pancreatic Cancer. Co-author DOI 10.1080/01635581.2016.1250921↗
  35. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreati… Co-author DOI 10.1097/md.0000000000005702↗
  36. Clinical characteristics of second primary pancreatic cancer. Last author DOI 10.1371/journal.pone.0179784↗
  37. Assessment of the Risk of Colorectal Cancer Survivors Developing a Second Primary Pancreatic Cancer. Last author DOI 10.5009/gnl16526↗
  38. Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2. Co-author DOI 10.1016/j.dld.2015.12.006↗
  39. Visceral Obesity is Associated with Poor Prognosis in Pancreatic Adenocarcinoma. Co-author DOI 10.1080/01635581.2016.1134600↗
  40. Statin Use and Its Impact on Survival in Pancreatic Cancer Patients. Co-author DOI 10.1097/md.0000000000003607↗
  41. Targeting the insulin growth factor-1 receptor with fluorescent antibodies enables high resolution imaging of human pancreatic cancer in orthotopic mouse model… Co-author DOI 10.18632/oncotarget.7576↗
  42. Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer. Co-author DOI 10.3349/ymj.2016.57.5.1124↗
  43. A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer. Co-author DOI 10.5009/gnl15186↗
  44. MUC1 selectively targets human pancreatic cancer in orthotopic nude mouse models. Co-author DOI 10.1371/journal.pone.0122100↗
  45. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. First author DOI 10.1007/s00262-014-1566-3↗
  46. Clinical usefulness of ¹⁸F-fluorodeoxyglucose-positron emission tomography in patients with locally advanced pancreatic cancer planned to undergo concurrent ch… Co-author DOI 10.1016/j.ijrobp.2014.05.030↗
  47. Notch pathway activation is associated with pancreatic cancer treatment failure. Last author DOI 10.1016/j.pan.2013.11.011↗
  48. Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea. Co-author DOI 10.1097/mpa.0000000000000163↗
  49. Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanc… Co-author DOI 10.1159/000375402↗
  50. Fatal liver injury complicated by percutaneous catheter drainage after distal pancreatosplenectomy in a patient with pancreatic cancer. Co-author DOI 10.14701/kjhbps.2014.18.2.64↗

Closest collaborators

The 25 strongest of 105 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Moon Jae Chung · 48 shared papers, 2013–2026 · strength 5.03
  2. Seungmin Bang · 47 shared papers, 2011–2025 · strength 4.75
  3. Seung Woo Park · 46 shared papers, 2011–2025 · strength 4.47
  4. Hee Seung Lee · 33 shared papers, 2016–2025 · strength 3.88
  5. Si Young Song · 45 shared papers, 2011–2024 · strength 3.84
  6. Jung Hyun Jo · 25 shared papers, 2014–2026 · strength 3.38
  7. Huapyong Kang · 11 shared papers, 2014–2024 · strength 1.16
  8. Chang Moo Kang · 11 shared papers, 2012–2024 · strength 1.11
  9. Jiyoung Keum · 7 shared papers, 2020–2025 · strength 1.07
  10. Ho Kyoung Hwang · 8 shared papers, 2012–2024 · strength 0.87
  11. Mi‐Suk Park · 7 shared papers, 2017–2024 · strength 0.85
  12. Sung Ill Jang · 4 shared papers, 2022–2026 · strength 0.80
  13. Woo Jung Lee · 9 shared papers, 2012–2022 · strength 0.67
  14. Jee Hoon Kim · 3 shared papers, 2024–2026 · strength 0.65
  15. Jae Bock Chung · 12 shared papers, 2013–2017 · strength 0.65
  16. Seung‐seob Kim · 4 shared papers, 2020–2024 · strength 0.56
  17. Kyung In Shin · 3 shared papers, 2024–2025 · strength 0.56
  18. Jae Hee Cho · 3 shared papers, 2022–2025 · strength 0.53
  19. Sang Hoon Lee · 5 shared papers, 2016–2024 · strength 0.46
  20. Jin Su Kim · 2 shared papers, 2024–2025 · strength 0.38
  21. Dawoon Jung · 3 shared papers, 2018–2023 · strength 0.38
  22. In Rae Cho · 5 shared papers, 2013–2021 · strength 0.37
  23. Chan Su Park · 2 shared papers, 2023–2024 · strength 0.34
  24. Min Sung Yoon · 2 shared papers, 2022–2024 · strength 0.31
  25. Seung‐Mo Hong · 2 shared papers, 2021–2024 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.